Aptevo Therapeutics has announced progress on APVO711, a dual-mechanism bispecific antibody that simultaneously blocks PD-L1 and activates CD40, potentially overcoming resistance to standard checkpoint inhibitors.
Aptevo Therapeutics has closed a $2.1 million financing through a registered direct offering and concurrent private placement priced at $1.19 per share.
Aptevo Therapeutics' mipletamig, combined with venetoclax and azacitidine, achieved a 100% remission rate within 30 days in Cohort 1 of the RAINIER trial for frontline AML.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.